PRECISION OPTICS CORPORATION, INC. Q4 FY2026 earnings call

• Operational Transformation: The past two years of investment in manufacturing capacity are yielding results, enabling profitable high-volume production. Q4 demonstrated substantial volume increases with improved efficiency.
• Satellite Communications Growth: A new U.S. space technology customer has placed initial engineering orders (~$100k total) for laser communication terminals. This program involves higher-level assemblies (electro-optics/electronics), potentially offering larger content per unit than existing programs. Production is expected to begin within 6-12 months.
• Sales & Marketing Expansion: Appointed Peter Thier as SVP of Sales and Marketing to drive pipeline growth and optimize utilization. Added sales development resources and expanded outbound marketing to target high-growth markets.
• Medical Device Ramps: The single-use ophthalmic line is ramping under a $3.5M follow-on order, leveraging efficiencies from the cystoscope line. Yields have stabilized at 94%.
• Defense Renewal: A large defense customer provided a $1.3M follow-on order and agreed to a multi-year renewal, establishing a manufacturing agreement for continuous production.
• Supply Chain Context: The slowdown in the existing satellite customer’s orders is due to constrained global launch capacity, not product issues. Recovery is expected by end of FY2027.

The company reported record revenue of $8.8 million in Q4 FY2026, up 42% year-over-year, and $31.5 million for the full year, up 65%. Gross margin improved to 25.3% in Q4 (vs. 13.0% prior year) and 17.2% for the full year. Adjusted EBITDA was positive $355,000 in Q4 and negative $2.1 million for the full year. Revenue breakdown by segment: Production revenue reached $8.0 million in Q4 (up 57%) and $28.1 million for the full year (doubling from prior year). Engineering revenue was $800,000 in Q4 and $3.5 million for the full year. Specific product lines included Single-use Cystoscope (yield/throughput improvements), Satellite Communications (record Q4 revenue, 99% yield), Single-use Ophthalmic ($413k Q4 revenue, 94% current yield), and Ross Optical ($1.5M Q4 revenue, up 55%, contributing meaningfully to profitability due to scalable fixed costs).

• FY2027 Revenue Guidance: Maintained flat guidance range of $30 million to $33 million, similar to FY2026.
• EBITDA Guidance: Revised upward; expects adjusted EBITDA between -$1.2 million and -$1.7 million, an improvement from FY2026's -$2.1 million.
• Quarterly Outlook: Anticipates quarterly losses in the first half of FY2027 due to a ~40% revenue reduction from the existing satellite customer in Q1 and further reductions in Q2. Expects a return to quarterly profitability by the end of the fiscal year.
• Long-term View: Confident in long-term growth driven by new satellite relationships, medical device ramps, and defense production, despite near-term headwinds.

• Temporary Revenue Decline: Significant reliance on a single large satellite customer whose orders have paused due to external launch capacity constraints, causing a projected 40% revenue drop in early FY2027.
• Margin Compression: Replacing high-margin satellite revenue with other business lines may not immediately restore profit levels, even if revenue targets are met.
• Execution Risk: Success depends on converting the new satellite engineering pipeline into production orders and successfully ramping yields on new medical lines (ophthalmic) faster than previous experiences.
• Market Uncertainty: The timeline for recovery in the satellite sector is uncertain, dependent on broader aerospace launch infrastructure availability.

Q: When will higher-margin, higher-content sub-assemblies from the new satellite customer flow through the bottom line? / A: Management indicated that production for this new customer is expected to start within 6-12 months, likely impacting results in the latter half of fiscal 2027. The company believes its manufacturing floor can scale these lines quickly without challenges, leveraging lessons learned over the past two years.

Q: What are the key milestones investors should watch for regarding the new satellite optical communications customer over the next 12-18 months? / A: Management outlined that for the existing customer, milestones include announcing new production orders followed by a 2-4 month supply chain restart. For the new customer, expect a series of engineering development orders over the coming months, followed by initial production orders and another 2-4 month startup period once orders are received.

Q: Is the primary competitive advantage in capacity/yield or IP/process knowledge for satellite terminals? / A: CEO Joe Forkey stated that the major competitive advantage is Intellectual Property (IP) regarding the design and manufacturing of sub-assemblies to hold super-tight tolerances required for inter-satellite laser comms. While capacity and yields are important, they are secondary to the proprietary process knowledge needed for such precision.

Q: Why did the existing satellite customer pause orders, and do they hold excess inventory? / A: The pause is due to restricted global satellite launch capacity, not product issues. The customer has excess inventory of sub-assemblies because their launch schedules were bottlenecked. Management expects demand to resume once launch capacity is resolved, viewing the pullback as temporary.

Q: Will the new medical programs (e.g., ophthalmic) face the same ramp-up challenges as the cystoscope line? / A: Management noted that while all new programs have startup challenges, the ophthalmic line achieved profitable margins much faster than the cystoscope line. They expect efficiency and yield improvements to occur more rapidly for newer programs as the team leverages established processes.